Prolactin inhibits BCL6 expression in breast cancer through a stat5a-dependent mechanism

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1711-1721

  Tran, Thai H ^a   Utama, Fransiscus E ^a   Lin, Justin ^a   Yang, Ning ^a   Sjolund, Ashley B ^a   Ryder, Amy ^a   Johnson, Kevin J ^a   Neilson, Lynn M ^a   Liu, Chengbao ^a   Brill, Kristin L ^a   Rosenberg, Anne L ^a   Witkiewicz, Agnieszka K ^a   Rui, Hallgeir ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; PROTEIN BCL 6; STAT5A PROTEIN; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME INHIBITION; EXPLANT; GENE CONTROL; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LACTATION; METASTASIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTITATIVE HISTOCHEMISTRY; REPORTER GENE; TISSUE CULTURE; TRANSACTIVATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELLS, CULTURED; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; PROGNOSIS; PROLACTIN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76749106107     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2314     Document Type: Article

References (50)

1. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997;11:179-86.
2. Hennighausen L, Robinson GW, Wagner KU, Liu W. Prolactin signaling in mammary gland development. J Biol Chem 1997; 272:7567-9.
3. Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 1999;10:131-57.
4. Cella N, Groner B, Hynes NE. Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells. Mol Cell Biol 1998;18:1783-92.
5. Neilson LM, Zhu J, Xie J, et al. Coactivation of Janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol 2007;21:2218-32.
6. Udy GB, Towers RP, Snell RG, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997;94:7239-44.
7. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100:2744-51.
8. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene 2003;22:4664-74.
9. Manhes C, Kayser C, Bertheau P, et al. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J Endocrinol 2006;190: 271-85.
10. Ren X, Zhang X, Kim AS, et al. Comparative genomics of susceptibility to mammary carcinogenesis among inbred rat strains: role of reduced prolactin signaling in resistance of the Copenhagen strain. Carcinogenesis 2008;29:177-85.
11. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27.
12. Barash I. Stat5 in the mammary gland: controlling normal development and cancer. J Cell Physiol 2006;209:305-13.
13. Humphreys RC, Hennighausen L. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 1999;10:685-94.
14. Ren S, Cai HR, Li M, Furth PA. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 2002; 21:4335-9.
15. Das R, Vonderhaar BK. Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 1996; 40:141-9.
16. Das R, Vonderhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 1997;2:29-39.
17. Gutzman JH, Rugowski DE, Nikolai SE, Schuler LA. Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. Oncogene 2007;26:6341-8.
18. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006;66:1824-32.
19. Nevalainen MT, Xie J, Torhorst J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004;22:2053-60.
20. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005;24:746-60.
21. Sultan AS, Brim H, Sherif ZA. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelialmesenchymal transition. Cancer Sci 2008;99:272-9.
22. Yamashita H, Nishio M, Ando Y, et al. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2006;13:885-93.
23. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004;108:665-71.
24. Strauss BL, Bratthauer GL, Tavassoli FA. STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types. Hum Pathol 2006;37:586-92.
25. Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008;13:93-103.
26. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
27. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A 1996;93:6947-52.
28. Meyer RD, Laz EV, Su T, Waxman DJ. Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5. Mol Endocrinol 2009;23:1914-26.
29. Fernandez de Mattos S, Essafi A, Soeiro I, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol 2004;24:10058-71.
30. Takeda N, Arima M, Tsuruoka N, et al. Bcl6 is a transcriptional repressor for the IL-18 gene. J Immunol 2003;171:426-31.
31. Bos R, van Diest PJ, van der Groep P, et al. Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1α (HIF-1α). Oncogene 2003;22:8948-51.
32. Logarajah S, Hunter P, Kraman M, et al. BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene 2003;22:5572-8.
33. Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 2002;16:1108-24.
34. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 2007;26:224-33.
35. Chen Y, Lin G, Huo JS, et al. Computational and functional analysis of growth hormone-regulated genes identifies the transcriptional repressor Bcl6 as a participant in GH-regulated transcription. Endocrinology. Epub 2009 Apr 30.
36. Scheeren FA, Naspetti M, Diehl S, et al. STAT5 regulates the selfrenewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol 2005;6:303-13.
37. Karnik SK, Chen H, McLean GW, et al. Menin controls growth of pancreatic β-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007;318:806-9.
38. Walker SR, Nelson EA, Zou L, et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009;7:966-76.
39. Utama FE, LeBaron MJ, Neilson LM, et al. Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 2006;188: 589-601.
40. Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997;89:3148-54.
41. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 1998;273:30218-24.
42. Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. Rna 2003;9: 493-501.
43. Dagvadorj A,KirkenRA, Leiby B,Karras J, NevalainenMT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 2008; 14:1317-24.
44. Plotnikov A, Li Y, Tran TH, et al. Oncogene-mediated inhibition of glycogen synthase kinase 3β impairs degradation of prolactin receptor. Cancer Res 2008;68:1354-61.
45. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66:5487-94.
46. LeBaron MJ, Xie J, Rui H. Evaluation of genome-wide chromatin library of Stat5 binding sites in human breast cancer. Mol Cancer 2005;4:6.
47. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
48. Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, Leonard WJ. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 2000;20:389-401.
49. Nakajima H, Brindle PK, Handa M, Ihle JN. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. EMBO J 2001;20:6836-44.
50. Alenzi FQ. BCL-6 prevents mammary epithelial apoptosis and promotes cell survival. J Pak Med Assoc 2008;58:494-7.